Defining a therapeutic range for adalimumab serum concentrations in the management of pediatric noninfectious uveitis, a step towards personalized treatment

Defining a therapeutic range for adalimumab serum concentrations in the management of pediatric noninfectious uveitis, a step towards personalized treatment

Abstract Background Adalimumab is currently considered the most efficacious anti-TNFα agent for childhood noninfectious uveitis (NIU). The objective of this study was to define a therapeutic range for adalimumab trough levels in the treatment of childhood NIU. Methods A retrospective, observational,...

Full description

Bibliographic Details
Main Authors: Jo L. Dehoorne, Helena Groth, Emma Carlé, Ilse De Schrijver, Celine Sys, Patricia Delbeke, Elke O. Kreps, Thomas Renson, Carolien Bonroy
Format: Article
Language:English
Published: BMC 2023-12-01
Series:Pediatric Rheumatology Online Journal
Subjects:
Pediatric noninfectious uveitis
Adalimumab
Therapeutic range
Trough levels
Therapeutic drug monitoring
Online Access:https://doi.org/10.1186/s12969-023-00928-2

Internet

https://doi.org/10.1186/s12969-023-00928-2

Similar Items